John P. Fruehauf
Oncology
101 The City Dr S
Orange, CA 92868
Orange, CA 92868
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: August 30, 2021
HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
Journal: Molecular cancer research : MCR
Published: October 22, 2018
Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.
Journal: Cancer chemotherapy and pharmacology
Published: May 28, 2018
Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
Journal: Cancer chemotherapy and pharmacology
Published: February 18, 2014
A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder.
Journal: Cancer chemotherapy and pharmacology
Published: March 01, 2013
Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study.
Journal: Gynecologic oncology
Published: March 20, 2012
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 30, 2011
Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis.
Journal: Matrix biology : journal of the International Society for Matrix Biology
Published: November 14, 2011
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 07, 2011
Reactive oxygen species: an Achilles' heel of melanoma?
Journal: Expert review of anticancer therapy
Published: November 06, 2008
Reactive oxygen species: a breath of life or death?
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 10, 2007
Last Updated: 09/26/2026